Last reviewed · How we verify
rhC1INH
At a glance
| Generic name | rhC1INH |
|---|---|
| Also known as | ruconest, Ruconest |
| Sponsor | University of Wisconsin, Madison |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
- Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation (PHASE2)
- Patient Registry to Evaluate the Real-world Safety of Ruconest®
- Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients (PHASE2)
- RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function (PHASE1)
- A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration (PHASE2)
- A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor (PHASE2)
- Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhC1INH CI brief — competitive landscape report
- rhC1INH updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI